VALUE OF DRUG PROVOCATION TEST

Size: px
Start display at page:

Download "VALUE OF DRUG PROVOCATION TEST"

Transcription

1 VALUE OF DRUG PROVOCATION TEST Professor MJ Torres Carlos Haya Hospital, University of Medicine, Malaga, Spain SESSION II: DIAGNOSIS OF HYPERSENSITIVITY TO NSAIDS IN PATIENTS WITH SELECTIVE RESPONSES

2 Disclosure In relation to this presentation, I declare that there are no conflicts of interest. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (eg. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

3 NSAIDs are the drugs more frequently prescribed worldwide

4 Children with a history of drug allergy N=866 ( ) % of drugs involved in the reaction P<0.001 Benzylpenicillin Amoxicillin AX-Clavulanic Cephalosporin Azithromycin Clarithromycin Ibuprofen Dipirone Aspirin Paracetamol Anesthesics Others Corzo JL. 2013

5 DRUG HYPERSENSITIVITY IN CHILDREN Hypersensitivity Non-hypersensitivity p (N, %) 128 (14.78) 738 (85.22) DRUGS (N, %) NSAID Betalactams Macrolides DRUGS (%) Ibuprofen Dypirone Paracetamol ASA 57 (44,53) 55 (42,97) 2 (1,56) 55 (63.2) 0 1 (14.3) 1 (50) 41 (5,56) 587 (79,54) 20 (2,71) 32 (36.8) 2 (100) 6 (85.7) 1 (50) 0, Zambonino MA. 2013

6 PATTERN OF COMSUMPTION OVER TIME 30 DDD/1,000 patient day Arilacetic Arilpropionic Coxib

7 CLASSIFICATION Timing Clinical manifestation Type of reaction Underlying disease Putative mechanism Acute (immediate to several hours exposure) Rhinitis/asthma Urticaria/angioedema Crossreactive Crossreactive Astma/rhinosinusitis/ nasal polyps Chronic urticaria COX-1 Inhib COX-1 Inhib Urticaria/angioedema Múltiple None COX-1 Inhib??? Urticaria/angioedema/ anaphylaxis Single Atopy?? Food allergy?? Drug alergy?? IgE-mediated Delayed (more than 24 hours after exposure) Fixed drug eruptions Severe bullous skin reactions MP drug eruptions Pneumonitis Aseptic meningitis Nephritis Contact and photocontact dermatitis Single or multiple Ninguna T cell mediated Kowalski ML, EAACI/ENDA and GA2LEN/HANNA. Allergy. 2011;66:818

8 CLASSIFICATION Type of reac+on Clinical manifesta+on Timing Underlying disease Cross reac+vity Puta+ve mechanism NSAIDs exacerbated respiratory disease (NERD) NSAIDs exacerbated cutaneous disease (NECD) NSAIDs induced ur+caria/ angioedema (NIUA) Single NSAIDs induced ur+/ angio/ anap (SNIUAA) Rhini%s/asthma Acute Asthma/ rhinosinusi%s Ur%caria/ angioedema Ur%caria/ angioedema Ur%caria/ angioedema/ anaphylaxis Chronic ur%caria No underlying chronic diseases No underlying chronic diseases YES Non- allergic Cox- 1 inhibi%on Cox- 1 inhibi%on Unknown, probably COX- 1 inhibi%on NO Allergic IgE- mediated Single NSAIDs- induced delayed reac+ons (SNIDR) various symptoms and organs involved Delayed No underlying chronic diseases T cell mediated ENDA NSAID TF (Kowalsky M, 2013)

9 Single NSAID induced urticaria/angioedema or anaphylaxis (SNIUAA) DEFINITION Immediate hypersensitivity reactions to a single NSAID or to several NSAIDs belonging to the same chemical group, manifesting as urticaria, angioedema and /or anaphylaxis. These subjects tolerate other chemically non-related NSAIDs, and usually do not have a history of chronic urticaria or asthma EPIDEMIOLOGY Up to 30% of all NSAIDs-induced skin reactions can represent a single drug-induced hypersensitivity reaction. The most frequently described causes of this type of reaction are pyrazolones, ibuprofen, diclofenac, aspirin and paracetamol. ENDA NSAID TF (Kowalsky M, 2013)

10 Single NSAID induced urticaria/angioedema or anaphylaxis (SNIUAA) PATHOMECHANISMS The clinical spectrum of symptoms and timing of reactions suggest an allergic type I mechanism. Reactions to very closely chemically related compounds within the same chemical group (e.g. to different pyrazolones) can occur suggesting epitope-specific immunological mechanism of reactions. In a small proportion of patients specific IgE can be detected in the skin test or in the serum, which may further support an IgE-mediated mechanism of drug hypersensitivity. CLINICAL PRESENTATION From mild urticaria and localized angioedema to laryngeal edema and anaphylaxis develop usually within minutes after a single NSAID intake. Reaction to a single NSAID usually appear at shorter intervals than NIUA and may develop within seconds or minutes. Patients usually present with a history of good tolerance to other chemically unrelated NSAIDs, including aspirin. Patients do not have a history of underlying chronic urticaria.

11 NSAIDs-induced delayed hypersensitivity reactions (NIDHR) DEFINITION Hypersensitivity reactions to a single NSAID appearing usually within hours after drug administration and manifesting by either skin symptoms (exanthema, fixed drug eruption), other organ specific symptoms (e. g. renal, pulmonary) or severe cutaneous adverse reactions (SCAR). EPIDEMIOLOGY The prevalence of NSAIDs induced delayed reactions is not known. The most common delayed reactions due to NSAIDs are maculopapular eruptions (MPE), fixed drug eruptions (FDE), contact dermatitis and photosensitivity reactions. Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug induced hypersensitivity syndrome (DIHS) can be also induced by NSAIDs. ENDA NSAID TF (Kowalsky M, 2013)

12 NSAIDs-induced delayed hypersensitivity reactions (NIDHR) PATHOMECHANISMS The pathomechanism of NIDHRs involves the stimulation of drug-specific CD4+ and CD8+ T cells through their T cell receptors (TCR) and represents a delayed type hypersensitivity. T cell dependent mechanisms have been documented in delayed urticaria, MPE induced by aceclophenac and metamizol and in SCAR induced by ibuprofen CLINICAL PRESENTATION They appear more than hours after exposure. The skin is the organ most frequently involved, usually with mild symptoms such as MPE, FDE, photosensitivity, delayed urticaria and contact dermatitis. Although less frequent, more severe reactions such as DIHS, AGEP and SCAR and organ-specific reactions may occur. ENDA NSAID TF (Kowalsky M, 2013)

13 659 patients with symptoms suggestive of NSAID hypersensitivity Selective 24% Crosssensitive 76% Doña I. Clin Exp Allergy 2010

14 63 children ( ) 43 (68.2%) OPT culprit + 25 (58,1%) OPT ASA + 18 (41,9%) OPT ASA - CROSS SENSITIVE SELECTIVE

15 DIFFERENTIAL CHARACTERISTICS OF SELECTIVE AND CROSS- SENSITIVE NSAID HYPERSENSITIVITY Cross sensitive Selective FREQUENCY 75% 25% TENDENCY DRUG CLINICAL SYMPTOMS Stable or Increase Ibuprofen ASA Urticaria Angioedema Blended Decrease Pyrazolones Urticaria Angioedema Anaphylaxis Delayed ATOPY YES NO FOOD ALLERGY YES? NO

16 How can we perform an accurate diagnosis????? How can we differentiate between selective and crosssensitivity hypersensitivity???? CLINICAL HISTORY SKIN TESTING IN VITRO TESTING NOT RELIABLE DRUG PROVOCATION TEST

17

18 DRUG PROVOCATION TEST Oral, Nasal and Bronchial route Under strict survelliance, trained personnel, special setting. Single blind placebo controlled ORAL PROVOCATION TEST Gold standard Sensitivity: 89% Specificity: 100% Time consuming Resources consuming Risky contraindications

19 ORAL DRUG PROVOCATION TEST Oral challenge with NSAID can be performed for three reasons: 1) with a culprit drug to confirm hypersensitivity; 2) with other than causative NSAIDs (usually challenge test with aspirin) in order to confirm/exclude crossreactivity, 3) with the most likely tolerated alternative drug. ENDA NSAID TF (Kowalsky M, 2013)

20 ORAL DRUG PROVOCATION TEST Time Day 1 Day 2 Day 3 7 a.m. Placebo 30 mg 100 mg* 150 mg** 10 a.m. Placebo 45 mg* 60 mg** 13 a.m. Placebo 60 mg* 100 mg** 150 mg* 325 mg** 650 mg Stevenson et al. * If the historical reaction was severe ** Iff the historical reaction was milder mg Cumulative dose of aspirin (mg) mg* 27 mg 17 mg* 44 mg 117 mg 312 mg Day 1: placebo Day 2: AAS 0 1 8:30 2 am 10:00 3 am 11:30 4 am 1:00 5 am 2:006 am Time (h) Nizakowska E et al.

21 DOSES RECOMENDED IN OPT DRUGS CUMMULATIVE DOSES (mg) Etoricoxib Celecoxib Paracetamol ADULTS Meloxicam 7,5-15 Nabumetone Diclofenac Metamizol Ibuprofen ASA 1º día: º dia: día º: º día: día º: º día: CHILDREN

22 ORAL DRUG PROVOCATION TEST 1. FEV1 decrease more than 20% from basal levels 2. Nasoocular symptoms 3. Skin symptoms POSITIVE 4. Total cummulative doses with good tolerance NEGATIVE

23 ORAL DRUG PROVOCATION TEST PREDICTIVE VALUE A positive oral provocation test (OPT) is confirmatory for suspected NSAIDs hypersensitivity. The test has been documented to have a very high (97,8 %) negative predictive value allowing for safe use of NSAIDs in most patients with equivocal history of hypersensitivity to NSAIDs. The positive predictive value of OPT is close to 100%. ENDA NSAID TF (Kowalsky M, 2013)

24 DRUG PROVOCATION TEST Nasal and/or bronchial symptoms Ur+caria/Angioedema Anaphylac+c reac+on NERD/AERD NECD/AECD NIUA SELECTIVE SNIUAAA NPT or BPT can be done Oral provoca+on test? Unequivocal History: DPT with ASA to exclude cross- reac+vity Equivocal history: DPT with culprit to exclude hypersensi+vity Positive ASA Positive ASA Negative NPT or BPT can be done Oral provoca+on test? NECD/AECD NIUA SELECTIVE SNIUAAA Tolerance for COX- 2 INHIBITORS Tolerance test with chemically non- realated NSAID ENDA NSAID TF (Kowalsky M)

25 DRUG PROVOCATION TEST Ur+caria/Angioedema Anaphylac+c reac+on SELECTIVE SNIUAAA Unequivocal History: DPT with ASA to exclude cross- reac+vity Equivocal history: DPT with culprit to exclude hypersensi+vity ASA Positive ASA Negative NECD/AECD NIUA SELECTIVE SNIUAAA Tolerance for COX- 2 INHIBITORS Tolerance test with chemically non- realated NSAID ENDA NSAID TF (Kowalsky M)

26 ORAL DRUG PROVOCATION TEST GRADING Single NSAID induced urticaria/angioedema or anaphylaxis (SNIUAA) In order to exclude a cross-reactive type of hypersensitivity an oral challenge with a chemically unrelated strong COX-1 inhibitor (preferable aspirin) may be considered (grade of recommendation D). If a SNIUAA is diagnosed, a patient can safely take other chemically unrelated NSAIDs (grade of recommendation D). If the tolerance to a possible alternative NSAIDs is not known, the first approach is to verify the possible existence of cross-intolerance by challenge with alternative NSAIDs (usually aspirin) (grade of recommendation D). ENDA NSAID TF (Kowalsky M, 2013)

27 DRUG PROVOCATION TEST!"#$%&'%($)*+,&-%.)+*/%+$0+% 1-+()2$(3)4%+$0+% 5,+/%2$4)"$2% ($)2,-60% 7()4%#(&8&*)+,&-% 5,+/%*94#(,+%2(96% 7()4% #(&8&*)+,&-% 5,+/%)4+$(-)+,8$% :;<1=% 7-%A&+/%)''$*+$2%)-2% -&-%)''$*+$2%)($)% B$0% B$0C:&% B$0% D)*94&#)#94)(% $(9#+,&-% B$0% B$0% B$0% B$0% <44$(6,*% #/&+&0$-0,+,8,+"% B$0% E#/&+&F#)+*/%+$0+G% :&% B$0C:&% B$0C:&% H&-+)*+%2$(3)+,+,0% B$0% :&% :&% :&% B$0% B$0%E#$('&(3% *)9+,&904"G% :&% B$0% B$0% B$0%E#$('&(3% *)9+,&904"G% :&% B$0% %

28 ORAL DRUG PROVOCATION TEST GRADING NSAIDs-induced delayed hypersensitivity reactions (NIDHR) There is no standardized protocol for DPT in delayed reactions to NSAIDs. DPT with culprit NSAIDs can be considered in MPE and FDE (grade of recommendation C). DPT with culprit NSAIDs are contraindicated in bullous drug eruptions such as toxic epidermal necrolysis, Stevens-Johnson Syndrome, AGEP (grade of recommendation C). DPT with alternative NSAIDs can be performed in all other situations (grade of recommendation D). ENDA NSAID TF (Kowalsky M, 2013)

29 CONCLUSIONS Ad 1. The oral challenge test with the culprit drug remains the gold standard to confirm the diagnosis of NSAIDs hypersensitivity, and all patients with equivocal history should be tested. However, oral challenge with a culprit NSAIDs is not recommended in the following situations: - Delayed type reactions (only patients with MPE, non-immediate urticaria or angiodema and FDE can be tested) - A history of severe anaphylaxis - Non controlled underlying chronic disease (asthma, urticaria) - Low pulmonary function test in an asthma patient - Concomitant disorders which could be aggravated by challenge or treatment ENDA NSAID TF (Kowalsky M, 2013)

30 CONCLUSIONS Ad 2. If aspirin is not the suspected culprit drug the patient should be challenged with aspirin to confirm/exclude cross-sensitivity. Positive reaction would confirm a cross-reactive type of hypersensitivity and negative reaction would speak for a single drug type reaction. If the causative drug was aspirin patient can be provoked with other strong COX-1 inhibitor to confirm the cross-reactive type of hypersensitivity. ENDA NSAID TF (Kowalsky M, 2013)

31 THANK YOU FUNDING SOURCES Health Ministery (FIS) PI05290 PIO61503 PIO61561 PI Science and Technology Ministery (MCYT) BQU Health Andalucia Ministery PI-0199/2007PI-0243/2007PI-0201/2007PI-0200/2007 Science, Innovation Andalucia Ministery CTS 570 FIS Tematic Network and Co-operative Research Centres RIRAAF (RD07/0064)

REVIEW ARTICLE. *HANNA European Network on Hypersensitivity to Aspirin and NonSteroidal Anti-Inflammatory Drugs. Abstract

REVIEW ARTICLE. *HANNA European Network on Hypersensitivity to Aspirin and NonSteroidal Anti-Inflammatory Drugs. Abstract Allergy REVIEW ARTICLE (NSAIDs) classification, diagnosis and management: review of the EAACI/ENDA # and GA2LEN/HANNA* M. L. Kowalski 1, J. S. Makowska 1, M. Blanca 2, S. Bavbek 3, G. Bochenek 4, J. Bousquet

More information

llergy Testing: When to test, when not to and what to do with the results

llergy Testing: When to test, when not to and what to do with the results llergy Testing: When to test, when not to and what to do with the results Kelly Maples, MD, FAAAAI, FACAAI Assistant Professor of Pediatrics and Internal Medicine CHKD/EVMS Sensitization Allergy The results

More information

Skin reactions associated with the use of oral terbinafine

Skin reactions associated with the use of oral terbinafine Skin reactions associated with the use of oral terbinafine Introduction The orally and topically active allylamine antifungal agent terbinafine (Lamisil ) has been approved for the Dutch market in 1991.

More information

Allergy Testing Clinical Coverage Policy No: 1N-1 Amended Date: October 1, 2015. Table of Contents

Allergy Testing Clinical Coverage Policy No: 1N-1 Amended Date: October 1, 2015. Table of Contents Table of Contents 1.0 Description of the Procedure, Product, or Service... 1 1.1 Definitions... 1 2.0 Eligible Beneficiaries... 2 2.1 Provisions... 2 2.1.1 General... 2 2.1.2 Specific... 2 2.2 Special

More information

Patterns of cross-reactivity

Patterns of cross-reactivity Patterns of cross-reactivity Werner J. Pichler, MD Division Allergology, RIA, Inselspital, University of Bern, CH 3010 Bern Switzerland ADR-AC GmbH Adverse Drug Reactions Analysis and Consulting Holligenstr

More information

Management of food allergy in Europe - An overview using Germany as an example

Management of food allergy in Europe - An overview using Germany as an example Management of food allergy in Europe - An overview using Germany as an example Disclosure In relation to this presentation, I declare that there are no conflicts of interest. Allergy Societies in Europe

More information

patient group direction

patient group direction DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

Internal Medicine Residency Program Rotation Curriculum

Internal Medicine Residency Program Rotation Curriculum University of California, Irvine Department of Medicine Internal Medicine Residency Program Rotation Curriculum I. Rotation Sites and Supervision Rotation Name: Allergy Clinic, UCIMC and Gottschalk Medical

More information

9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance

9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical

More information

Emergency Anaphylaxis Management: Opportunities for Improvement. Ronna Campbell, MD, PhD August 31, 2015

Emergency Anaphylaxis Management: Opportunities for Improvement. Ronna Campbell, MD, PhD August 31, 2015 Emergency Anaphylaxis Management: Opportunities for Improvement Ronna Campbell, MD, PhD August 31, 2015 disclosures Anaphylaxis Roundtable discussion held at the 2014 American College of Allergy, Asthma

More information

5.07.09. Aubagio. Aubagio (teriflunomide) Description

5.07.09. Aubagio. Aubagio (teriflunomide) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)

More information

Stowe School Medications Policy

Stowe School Medications Policy INTRODUCTION Most pupils will need medication at some stage of their school life. Although this will mainly be for short periods there are a few pupils with chronic conditions who may require regular medication

More information

Allergy Testing Test Request and Result Interpretation. Learning Objectives

Allergy Testing Test Request and Result Interpretation. Learning Objectives Allergy Testing Test Request and Result Interpretation Dr. Kareena Schnabl, MSc, PhD, FCACB Clinical Biochemist, Genetic Laboratory Services University of Alberta Hospital Newborn Screening & Biochemical

More information

IgE-mediated Food Allergies

IgE-mediated Food Allergies The image part with relationship ID rid13 was not found in the file. IgE-mediated Food Allergies Kirsi M. Järvinen-Seppo, MD, PhD Click to edit Presenter Name Dept. of Medicine, Division of Allergy, Asthma

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

Over the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada

Over the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada Background Over the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada The use of medications or drugs by non-physician health professionals is evolving and is linked to collaboration

More information

Anaphylaxis and other adverse events

Anaphylaxis and other adverse events Anaphylaxis and other adverse events Aim: To be able to manage anaphylaxis and other adverse events correctly Learning outcomes Define local and systemic adverse events Distinguish between anaphylaxis

More information

Drug allergy. David A. Khan, MD, a and Roland Solensky, MD b. Dallas, Tex, Corvallis, Ore

Drug allergy. David A. Khan, MD, a and Roland Solensky, MD b. Dallas, Tex, Corvallis, Ore Drug allergy David A. Khan, MD, a and Roland Solensky, MD b Dallas, Tex, Corvallis, Ore Drug allergy is one type of adverse reaction to drugs and encompasses a spectrum of hypersensitivity reactions with

More information

Cutaneous adverse drug reactions in a tertiary hospital in South-east Asia

Cutaneous adverse drug reactions in a tertiary hospital in South-east Asia Hong Kong J. Dermatol. Venereol. (2015) 23, 105-112 Original Article Cutaneous adverse drug reactions in a tertiary hospital in South-east Asia JYY Pang, SM Pang, HY Koh The clinical spectrum of cutaneous

More information

NCCP Chemotherapy Protocol. Afatinib Monotherapy

NCCP Chemotherapy Protocol. Afatinib Monotherapy Afatinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

More information

ASTHMA IN INFANTS AND YOUNG CHILDREN

ASTHMA IN INFANTS AND YOUNG CHILDREN ASTHMA IN INFANTS AND YOUNG CHILDREN What is Asthma? Asthma is a chronic inflammatory disease of the airways. Symptoms of asthma are variable. That means that they can be mild to severe, intermittent to

More information

Antibiotic Guidelines: Ear Nose and Throat (ENT) Infections. Contents

Antibiotic Guidelines: Ear Nose and Throat (ENT) Infections. Contents Antibiotic Guidelines: Ear Nose and Throat (ENT) Infections. Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine

More information

Glossary of Terms. Section Glossary. of Terms

Glossary of Terms. Section Glossary. of Terms Glossary of Terms Section Glossary of Terms GLOSSARY Acute: Symptoms which can occur suddenly with a short and severe course. Adrenaclick /Generic Adrenaclick : a single use epinephrine auto-injector that

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

Alarge proportion of the population is exposed to nonsteroidal

Alarge proportion of the population is exposed to nonsteroidal REVIEW ARTICLE Clinical Management of Nonsteroidal Anti-inflammatory Drug Hypersensitivity Abstract: Hypersensitivity diseases caused by nonsteroidal antiinflammatory agents are relatively common in the

More information

Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd.

Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd. Causality Assessment in Practice Pharmaceutical Industry Perspective Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd., Basel Disclaimer: The opinions expressed in this presentation are

More information

Allergy and Immunology Competency Based Goals and Objectives

Allergy and Immunology Competency Based Goals and Objectives Allergy and Immunology Competency Based Goals and Objectives COMPETENCY 1. Patient Care. Provide family centered patient care that is developmentally and age appropriate, compassionate, and effective for

More information

EBMT Education Day for Nurses and AHPs April 2012 Skin care: not every rash is GVHD

EBMT Education Day for Nurses and AHPs April 2012 Skin care: not every rash is GVHD EBMT Education Day for Nurses and AHPs April 2012 Skin care: not every rash is GVHD Eileen Parry Consultant Dermatologist Tameside Hospital Foundation Trust Overview How to assess a patient with a rash

More information

Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs)

Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs) EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products

More information

CAUSES Pressure changes Respiratory infection-congestion or sinus infection

CAUSES Pressure changes Respiratory infection-congestion or sinus infection Page 1 of 6 pages NOTE Contact Surgeon before giving any medication marked with an asterisk. In an emergency or during Loss of Signal, begin appropriate treatment; then call Surgeon as soon as possible.

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because

More information

Anaphylaxis / Urticaria / Angioedema HSJ 29/02/12

Anaphylaxis / Urticaria / Angioedema HSJ 29/02/12 Anaphylaxis / Urticaria / Angioedema HSJ 29/02/12 Case Study Female, 42,? Penicillin Allergy After 1 tab amoxyl, tongue/throat swelling, lips, ears Collapse, given adrenaline Had amoxycillin several times

More information

5. Treatment of Asthma in Children

5. Treatment of Asthma in Children Treatment of sthma in hildren 5. Treatment of sthma in hildren 5.1 Maintenance Treatment 5.1.1 rugs Inhaled Glucocorticoids. Persistent wheezing in children under the age of three can be controlled with

More information

Allergy Evaluation-What it all Means & Role of Allergist

Allergy Evaluation-What it all Means & Role of Allergist Allergy Evaluation-What it all Means & Role of Allergist Sai R. Nimmagadda, M.D.. Associated Allergists and Asthma Specialists Ltd. Clinical Assistant Professor Of Pediatrics Northwestern University Chicago,

More information

Corporate Medical Policy Allergy Immunotherapy (Desensitization)

Corporate Medical Policy Allergy Immunotherapy (Desensitization) Corporate Medical Policy Allergy Immunotherapy (Desensitization) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: allergy_immunotherapy 7/1979 11/2014 11/2015 10/2015 Description

More information

ZOVIRAX Cold Sore Cream

ZOVIRAX Cold Sore Cream Data Sheet ZOVIRAX Cold Sore Cream Aciclovir 5% w/w Presentation Topical cream Indications ZOVIRAX Cold Sore Cream is indicated for the treatment of Herpes simplex virus infections of the lips and face

More information

The Diagnosis of Food Allergy

The Diagnosis of Food Allergy The Diagnosis of Food Allergy Robert A. Wood, MD Professor of Pediatrics and International Health Director, Pediatric Allergy and Immunology Johns Hopkins University School of Medicine Disclosures Research

More information

European Respiratory Society (ERS), The European Lung White Book Respiratory Health and Disease in Europe, 2013. 3

European Respiratory Society (ERS), The European Lung White Book Respiratory Health and Disease in Europe, 2013. 3 EFA response to the European Commission public consultation on fragrance allergens in the framework of Regulation (EC) No. 1223/2009 of the European Parliament and of the Council on cosmetic products The

More information

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed

More information

Betalactam allergy: a prospective study in children

Betalactam allergy: a prospective study in children Allergy 2007: 62: 42 46 Ó 2007 The Authors Journal compilation Ó 2007 Blackwell Munksgaard DOI: 10.1111/j.1398-9995.2006.01246.x Original article Allergy to betalactam antibiotics in children: a prospective

More information

Guidelines for anaphylaxis emergency medication (adrenaline [epinephrine] autoinjector) prescription

Guidelines for anaphylaxis emergency medication (adrenaline [epinephrine] autoinjector) prescription Guidelines for anaphylaxis emergency medication (adrenaline [epinephrine] autoinjector) prescription Introduction The aim of these guidelines is to outline the appropriate prescription of adrenaline (epinephrine)

More information

Clinical Performance Director of Nursing Allison Bussey

Clinical Performance Director of Nursing Allison Bussey PGD 0314 Patient Group Direction Administration of Adrenaline (Epinephrine) 1:1000 (1mg/ml) Injection By Registered Nurses employed by South Staffordshire & Shropshire Healthcare Foundation NHS Trust This

More information

Name of Policy: Antigen Leukocyte Cellular Antibody Test (ALCAT)

Name of Policy: Antigen Leukocyte Cellular Antibody Test (ALCAT) Name of Policy: Antigen Leukocyte Cellular Antibody Test (ALCAT) Policy #: 165 Latest Review Date: February 2015 Category: Laboratory Policy Grade: C Background/Definitions: As a general rule, benefits

More information

Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients

Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Developed by the Mid Atlantic Renal Coalition and the Kidney End of Life Coalition September 2009 This project was supported,

More information

MEDICATION MANUAL Policy & Procedure

MEDICATION MANUAL Policy & Procedure MEDICATION MANUAL Policy & Procedure TITLE: Section: Initial Management of Anaphylaxis Following Immunization Medication Specific NUMBER: MM 20-005 Date Issued: October 2009 Source: Distribution: Capital

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1)

Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) This Influenza Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses (

More information

September 2008 [KT 168] Sub. Code: 2063 M.D. DEGREE EXAMINATION Branch XVII Tuberculosis and Respiratory Diseases NON-TUBERCULOSIS CHEST DISEASES Common to Part II Paper II - (Old /New/Revised Regulations)

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

Primary Care Paramedic. Diphenhydramine (Benadryl) Certification Package

Primary Care Paramedic. Diphenhydramine (Benadryl) Certification Package Primary Care Paramedic Diphenhydramine (Benadryl) Certification Package 1 Welcome to the Primary Care Paramedic Diphenhydramine Certification package! The addition of Benadryl to your list of medications

More information

Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer )

Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer ) Departments of Haematology, Nephrology and Pharmacy Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer ) [Care Pathway Review Date] Guidance for use This Care Pathway is intended

More information

Vaccine Protocol Agreement. Name of Pharmacy: Address: City, State, Zip:

Vaccine Protocol Agreement. Name of Pharmacy: Address: City, State, Zip: Vaccine Protocol Agreement Name of Pharmacy: Address: City, State, Zip: This Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses ( Nurses

More information

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System 1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID

More information

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007

More information

PHARMACOVIGILANCE GUIDELINES

PHARMACOVIGILANCE GUIDELINES PHARMACOVIGILANCE GUIDELINES What is Pharmacovigilance? Pharmacovigilance is defined as the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Maintenance of abstinence in alcohol dependence

Maintenance of abstinence in alcohol dependence Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly

More information

POLICY SERVICES ADVISORY

POLICY SERVICES ADVISORY POLICY SERVICES ADVISORY Volume 12, Number 2 April 2015 CONTENTS Policy Advisory No. 114 JLCG Emergency Administration of Medications to Students JLCG-R Emergency Administration of Medications to Students

More information

ICD 10 is here!!! Getting Ready for ICD-10: Cracking the Code. CPT vs ICD. Definitions. WHY do we have to use these codes?

ICD 10 is here!!! Getting Ready for ICD-10: Cracking the Code. CPT vs ICD. Definitions. WHY do we have to use these codes? Getting Ready for ICD-10: Cracking the Code Marshall Grodofsky, MD, FAAAAI Priya J. Bansal, MD FAAAAI Workshop 2011 March 1, 2014 San Diego, CA ICD 10 is here!!! Will be used for Outpatient services October

More information

Summary of the risk management plan (RMP) for Otezla (apremilast)

Summary of the risk management plan (RMP) for Otezla (apremilast) EMA/741412/2014 Summary of the risk management plan (RMP) for Otezla (apremilast) This is a summary of the risk management plan (RMP) for Otezla, which details the measures to be taken in order to ensure

More information

Summary of the risk management plan (RMP) for Tritanrix HB [Diphtheria, tetanus, pertussis (whole cell) and hepatitis B (rdna) vaccine (adsorbed)]

Summary of the risk management plan (RMP) for Tritanrix HB [Diphtheria, tetanus, pertussis (whole cell) and hepatitis B (rdna) vaccine (adsorbed)] EMA/14365/2014 Summary of the risk management plan (RMP) for Tritanrix HB [Diphtheria, tetanus, pertussis (whole cell) and hepatitis B (rdna) vaccine (adsorbed)] Overview of disease epidemiology Diphtheria

More information

Administering epinephrine for acute anaphylactic type allergic reactions

Administering epinephrine for acute anaphylactic type allergic reactions Administering epinephrine for acute anaphylactic type allergic reactions Training for first aiders in schools People known to be allergic (1.5 hours) MAJ-2013-2 2 Goal of program Reduce the morbidity and

More information

The Physician s Perspective of ICD-10

The Physician s Perspective of ICD-10 May 14, 2015 The Physician s Perspective of ICD-10 Moderator: J. Allen Meadows, MD, FACAAI Advocacy Council of ACAAI Therese Jorwic, MPH, RHIA, CCS, CCS-P, FAHIMA Provided by: Disclosures Presenter Therese

More information

8. Strategies in Patients at Risk for Allergic Reactions to IV Contrast for CT

8. Strategies in Patients at Risk for Allergic Reactions to IV Contrast for CT Updated 7/14/09 UAB Department of Radiology Guidelines for Administering Gadolinium-based and Iodine-based Intravenous Contrast Agents in Patients with Renal Dysfunction or at Risk for Adverse Reactions

More information

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 5/2015

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 5/2015 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)

More information

Adrenaline autoinjector (EpiPen) for acute allergic anaphylaxis

Adrenaline autoinjector (EpiPen) for acute allergic anaphylaxis for acute allergic anaphylaxis This review of adrenaline autoinjector was first published in December 2003. This update describes the change to the PBS listing to allow prescribing immediately after hospital

More information

PRODUCT INFORMATION PANAMAX

PRODUCT INFORMATION PANAMAX NAME OF THE MEDICINE Non-proprietary Name Paracetamol PRODUCT INFORMATION PANAMAX DESCRIPTION Each tablet contains paracetamol 500 mg. The inactive ingredients are: maize starch, purified talc, pregelatinised

More information

Drug Hypersensitivity Reactions. Morning Report April 18, 2005

Drug Hypersensitivity Reactions. Morning Report April 18, 2005 Drug Hypersensitivity Reactions Morning Report April 18, 2005 Drug Reactions: two categories Predictable ~80% of all drug reactions Secondary to the pharmacologic actions of the drug and are generally

More information

Allergies and Autoimmune Inner Ear Disease

Allergies and Autoimmune Inner Ear Disease Allergies and Autoimmune Inner Ear Disease Allergy is the term used to describe an over-reaction of the body to a substance that is normally harmless to most people. This substance is called an allergen,

More information

Title: Antibiotic Guideline for Acute Pelvic Inflammatory Disease

Title: Antibiotic Guideline for Acute Pelvic Inflammatory Disease Title: Antibiotic Guideline for Acute Pelvic Inflammatory Disease Version 3 Date ratified December 2007 Review date December 2009 Ratified by NUH Antimicrobial Guidelines Committee Gynaecology Directorate

More information

MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)

MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,

More information

SMO: Anaphylaxis and Allergic Reactions

SMO: Anaphylaxis and Allergic Reactions REGION I EMERGENCY MEDICAL SERVICES STANDING MEDICAL ORDERS EMT Basic SMO: Anaphylaxis and Allergic Reactions Overview: Allergic reactions can vary in severity from a mild reaction consisting of hives

More information

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die

More information

EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - SEVERE AND SERIOUS HEPATIC REACTIONS -

EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - SEVERE AND SERIOUS HEPATIC REACTIONS - The European Agency for the Evaluation of Medicinal Products Post-authorisation evaluation of medicines for human use London, 12 March 2001 Doc. Ref: EMEA/H/5611/01/en EMEA PUBLIC STATEMENT ON LEFLUNOMIDE

More information

Allergies: ENT and Allergy Center of Missouri YOUR GUIDE TO TESTING AND TREATMENT. University of Missouri Health Care

Allergies: ENT and Allergy Center of Missouri YOUR GUIDE TO TESTING AND TREATMENT. University of Missouri Health Care Allergies: YOUR GUIDE TO TESTING AND TREATMENT ENT and Allergy Center of Missouri University of Missouri Health Care 812 N. Keene St., Columbia, MO 65201 (573) 817-3000 www.muhealth.org WHAT CAUSES ALLERGIES

More information

OCCUPATIONAL SKIN DISEASES IN NURSES

OCCUPATIONAL SKIN DISEASES IN NURSES International Journal of Occupational Medicine and Environmental Health, 2003; 16(3): 241 247 OCCUPATIONAL SKIN DISEASES IN NURSES RUTA TELKSNIENE 1 and VIDMANTAS JANUSKEVICIUS 2 1 Department of Environmental

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San

More information

EXHIBIT H SETTLEMENT ELIGIBILITY CRITERIA. a) pharmacy records reflecting the dispensing of Bextra and/or Celebrex to the Class Member; or

EXHIBIT H SETTLEMENT ELIGIBILITY CRITERIA. a) pharmacy records reflecting the dispensing of Bextra and/or Celebrex to the Class Member; or EXHIBIT H SETTLEMENT ELIGIBILITY CRITERIA 1. PRODUCT IDENTIFICATION DOCUMENTATION In order to be eligible for compensation under the Settlement Agreement, each Claimant must provide evidence of the Class

More information

SSS01 Health Management and Medication Policy

SSS01 Health Management and Medication Policy An Australian tradition since 1883 Cricos Provider number 00197D SSS01 Health Management and Medication Policy PURPOSE This policy is established to ensure Stott s Colleges meets its commitments to maintaining

More information

Hospital Outpatient Coding and Billing Information Sheet for Neulasta and NEUPOGEN

Hospital Outpatient Coding and Billing Information Sheet for Neulasta and NEUPOGEN Hospital Outpatient Coding and Billing Information Sheet for Neulasta and Neulasta Delivery Kit Neulasta Prefilled Syringe For assistance contact 1-844-MYNEULASTA (1-844-696-3852) or visit www.amgenassistonline.com

More information

The challenge of food allergies

The challenge of food allergies 2:15 3 pm Food Allergies and Food Intolerance: Update on Guidelines Presenter Disclosure Information The following relationships exist related to this presentation: Maria Garcia-Lloret, MD: No financial

More information

Antibiotic Prophylaxis for the Prevention of Infective Endocarditis and Prosthetic Joint Infections for Dentists

Antibiotic Prophylaxis for the Prevention of Infective Endocarditis and Prosthetic Joint Infections for Dentists PRACTICE ADVISORY SERVICE FAQ 6 Crescent Road, Toronto, ON Canada M4W 1T1 T: 416.961.6555 F: 416.961.5814 Toll Free: 1.800.565.4591 www.rcdso.org Antibiotic Prophylaxis for the Prevention of Infective

More information

Epinephrine Auto Injector Interim Policy (Amended March 12, 2008)

Epinephrine Auto Injector Interim Policy (Amended March 12, 2008) Epinephrine Auto Injector Interim Policy (Amended March 12, 2008) Pursuant to the authority conferred by N.J.S.A. 26:2K-47.1, et seq., the Department of Health and Senior Services (the Department) shall

More information

Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement

Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement A Copy of this page signed by all three parties should be retained in the

More information

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE)

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE) European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMEA/HMPC/745582/2009 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH

More information

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James

More information

Pharmacovigilance Study of Adverse Cutaneous Drug Reactions in a Tertiary Care Hospital

Pharmacovigilance Study of Adverse Cutaneous Drug Reactions in a Tertiary Care Hospital RESEARCH ARTICLE Pharmacovigilance Study of Adverse Cutaneous Drug Reactions in a Tertiary Care Hospital Tejas Acharya, Dimple Mehta, Hiral Shah, Jayendra Dave C U Shah Medical College and Hospital, Surendranagar,

More information

How to Submit a School Epinephrine Report

How to Submit a School Epinephrine Report 1. INTRODUCTION AND INSTRUCTIONS Dear School Nurse, The revised Regulations Governing the Administration of Prescription Medications in Public and Private Schools (105 CMR 210.000) require schools to submit

More information

DNH 120 Management of Emergencies

DNH 120 Management of Emergencies Revised: Fall 2015 DNH 120 Management of Emergencies COURSE OUTLINE Prerequisites: None Course Description: Studies the various medical emergencies and techniques for managing emergencies in the dental

More information

EVERYTHING YOU WANTED TO KNOW ABOUT ALLERGIES

EVERYTHING YOU WANTED TO KNOW ABOUT ALLERGIES EVERYTHING YOU WANTED TO KNOW ABOUT ALLERGIES I. ABOUT ALLERGIES A. What is an allergy? Allergies are hypersensitivity reactions of the body s immune system to specific substances we come in contact with

More information

William E. Berger, M.D., M.B.A. Clinical Professor Department of Pediatrics Division of Allergy and Immunology University of California, Irvine

William E. Berger, M.D., M.B.A. Clinical Professor Department of Pediatrics Division of Allergy and Immunology University of California, Irvine Allergic Reactions & Access to Emergency Response William E. Berger, M.D., M.B.A. Clinical Professor Department of Pediatrics Division of Allergy and Immunology University of California, Irvine Mechanistic

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

ALBERTA IMMUNIZATION POLICY GUIDELINES

ALBERTA IMMUNIZATION POLICY GUIDELINES ALBERTA IMMUNIZATION POLICY GUIDELINES Hepatitis Vaccines. Hepatitis A Vaccines Refer to the vaccine product monograph and the Canadian Immunization Guide for further Product monographs are available on

More information

Prescribing Framework for Donepezil in the Treatment and Management of Dementia

Prescribing Framework for Donepezil in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP

More information

Nursing 113. Pharmacology Principles

Nursing 113. Pharmacology Principles Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics

More information

AMPYRA (dalfampridine) Important Safety Information

AMPYRA (dalfampridine) Important Safety Information NEWS RELEASE Acorda to Present New rhigm22 and AMPYRA (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 10/7/2015 ARDSLEY, N.Y.--(BUSINESS

More information

MONROE SCHOOL DISTRICT NO. 103 No.: P5432 MONROE PUBLIC SCHOOLS STUDENTS BOARD POLICY PROCEDURE P5432 MEDICATION AT SCHOOL

MONROE SCHOOL DISTRICT NO. 103 No.: P5432 MONROE PUBLIC SCHOOLS STUDENTS BOARD POLICY PROCEDURE P5432 MEDICATION AT SCHOOL Page: 1 of 9 MONROE PUBLIC SCHOOLS STUDENTS BOARD POLICY PROCEDURE P5432 MEDICATION AT SCHOOL Each school principal shall authorize at least two staff members to administer prescribed or nonprescribed

More information

NUVIGIL (armodafinil) oral tablet

NUVIGIL (armodafinil) oral tablet NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information